Literature DB >> 29218254

Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling.

Vincent Crenn1,2,3, Kevin Biteau1,2, Jérôme Amiaud1,2, Clotilde Dumars4, Romain Guiho1,2, Luciano Vidal1,2, Louis-Romée Le Nail1,2,5, Dominique Heymann1,2, Anne Moreau4, François Gouin1,2,3, Françoise Redini1,2.   

Abstract

Osteosarcoma, the most common malignant primary bone tumor, is currently treated with chemotherapy and surgery. The effectiveness of chemotherapy is evaluated by means of histological analysis of tumor necrosis, known as "the Huvos score". However, 25% of the patients initially considered good responders will relapse. In our practice, strong tissue heterogeneity around the residual viable cells of the osteosarcoma is observed, but this is not taken into account by the Huvos score, as it is only an average. The objective is to determine whether heterogeneity in the osteosarcoma's microenvironment can play a role in the histological response to chemotherapy. Two complementary approaches have been developed: (i) the therapeutic response to several monotherapies (ifosfamide, cisplatin, doxorubicin) has been compared to tumor growth and the necrosis levels in different preclinical syngeneic osteosarcoma models, mimicking various microenvironments by injecting the tumor cells into subcutaneous, intra-muscular paratibial, or intra-osseous sites; (ii) a retrospective analysis was performed on patients' osteoblastic osteosarcoma biopsies. Tissue localization mapping of residual live tumor cell colonies was evaluated for potential correlation with overall survival. The results of the preclinical studies showed a difference in tumor growth depending on the osteosarcoma model, with a higher rate in bone sites compared to subcutaneous tumors. For the therapeutic response, a higher response to doxorubicin was observed in the intra-osseous model compared to the intra-muscular model for tumor growth (P = 0.013) and necrosis (P = 0.007). These data strongly suggest that the microenvironment plays a role in how osteosarcoma responds to chemotherapy. The retrospective analysis showed no significant survival difference between residual cell sites, although the soft tissues may be seen as a potential negative factor.

Entities:  

Keywords:  Osteosarcoma; histological analysis; microenvironment; murine model; retrospective analysis

Year:  2017        PMID: 29218254      PMCID: PMC5714759     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  45 in total

1.  A preclinical model for experimental chemotherapy of human head and neck cancer.

Authors:  K Sommer; S O Peters; I H Robins; M Raap; G J Wiedemann; S Remmert; P Sieg; C Bittner; T Feyerabend
Journal:  Int J Oncol       Date:  2001-06       Impact factor: 5.650

Review 2.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

3.  Evidence for the osteosarcoma stem cell.

Authors:  C Parker Gibbs; Padraic P Levings; Steven C Ghivizzani
Journal:  Curr Orthop Pract       Date:  2011-07

Review 4.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

5.  Doxorubicin gradients in human breast cancer.

Authors:  J Lankelma; H Dekker; F R Luque; S Luykx; K Hoekman; P van der Valk; P J van Diest; H M Pinedo
Journal:  Clin Cancer Res       Date:  1999-07       Impact factor: 12.531

6.  Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Authors:  Penelope D Ottewell; Hannu Mönkkönen; Mark Jones; Diane V Lefley; Robert E Coleman; Ingunn Holen
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

Review 7.  Osteosarcoma: A Meta-Analysis and Review of the Literature.

Authors:  Jill C Friebele; Jeffrey Peck; Xueliang Pan; Mahmoud Abdel-Rasoul; Joel L Mayerson
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2015-12

Review 8.  Prognostic factors in osteosarcoma: a critical review.

Authors:  A M Davis; R S Bell; P J Goodwin
Journal:  J Clin Oncol       Date:  1994-02       Impact factor: 44.544

9.  Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review.

Authors:  G M O'Kane; K A Cadoo; E M Walsh; R Emerson; P Dervan; C O'Keane; B Hurson; G O'Toole; S Dudeney; E Kavanagh; S Eustace; D N Carney
Journal:  Clin Sarcoma Res       Date:  2015-07-14

10.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.

Authors:  Wanjuan Yang; Jorge Soares; Patricia Greninger; Elena J Edelman; Howard Lightfoot; Simon Forbes; Nidhi Bindal; Dave Beare; James A Smith; I Richard Thompson; Sridhar Ramaswamy; P Andrew Futreal; Daniel A Haber; Michael R Stratton; Cyril Benes; Ultan McDermott; Mathew J Garnett
Journal:  Nucleic Acids Res       Date:  2012-11-23       Impact factor: 16.971

View more
  12 in total

1.  Composite Hydrogel Embedded with Porous Microspheres for Long-Term pH-Sensitive Drug Delivery.

Authors:  Xifeng Liu; Kevin A Fundora; Zifei Zhou; Alan Lee Miller; Lichun Lu
Journal:  Tissue Eng Part A       Date:  2018-11-20       Impact factor: 3.845

2.  Prediction of Histologic Neoadjuvant Chemotherapy Response in Osteosarcoma Using Pretherapeutic MRI Radiomics.

Authors:  Amine Bouhamama; Benjamin Leporq; Wassef Khaled; Angéline Nemeth; Mehdi Brahmi; Julie Dufau; Perrine Marec-Bérard; Jean-Luc Drapé; François Gouin; Axelle Bertrand-Vasseur; Jean-Yves Blay; Olivier Beuf; Frank Pilleul
Journal:  Radiol Imaging Cancer       Date:  2022-09

3.  Signature of the vascular tumor microenvironment as a marker of the therapeutic response to doxorubicin in a preclinical model of osteosarcoma.

Authors:  Vincent Crenn; Jérôme Amiaud; Anne Gomez-Brouchet; Vincent Potiron; François Gouin; Philippe Rosset; Louis-Romée Le Nail; Luciano Vidal; Helios Bertin; Régis Brion; Guillaume Tran; Franck Verrecchia; Isabelle Corre; Françoise Redini
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

Review 4.  Canine and murine models of osteosarcoma.

Authors:  Jessica Beck; Ling Ren; Shan Huang; Erika Berger; Kathleen Bardales; Joshua Mannheimer; Christina Mazcko; Amy LeBlanc
Journal:  Vet Pathol       Date:  2022-03-26       Impact factor: 3.157

Review 5.  Small animal models for the study of bone sarcoma pathogenesis:characteristics, therapeutic interests and limitations.

Authors:  Camille Jacques; Nathalie Renema; Frederic Lezot; Benjamin Ory; Carl R Walkley; Agi E Grigoriadis; Dominique Heymann
Journal:  J Bone Oncol       Date:  2018-02-21       Impact factor: 4.072

6.  Jaw osteosarcoma models in mice: first description.

Authors:  Hélios Bertin; Romain Guilho; Régis Brion; Jérôme Amiaud; Séverine Battaglia; Anne Moreau; Anne Brouchet-Gomez; Julie Longis; Benoit Piot; Dominique Heymann; Pierre Corre; Françoise Rédini
Journal:  J Transl Med       Date:  2019-02-27       Impact factor: 5.531

Review 7.  Sarcoma treatment in the era of molecular medicine.

Authors:  Thomas Gp Grünewald; Marta Alonso; Sofia Avnet; Ana Banito; Stefan Burdach; Florencia Cidre-Aranaz; Gemma Di Pompo; Martin Distel; Heathcliff Dorado-Garcia; Javier Garcia-Castro; Laura González-González; Agamemnon E Grigoriadis; Merve Kasan; Christian Koelsche; Manuela Krumbholz; Fernando Lecanda; Silvia Lemma; Dario L Longo; Claudia Madrigal-Esquivel; Álvaro Morales-Molina; Julian Musa; Shunya Ohmura; Benjamin Ory; Miguel Pereira-Silva; Francesca Perut; Rene Rodriguez; Carolin Seeling; Nada Al Shaaili; Shabnam Shaabani; Kristina Shiavone; Snehadri Sinha; Eleni M Tomazou; Marcel Trautmann; Maria Vela; Yvonne Mh Versleijen-Jonkers; Julia Visgauss; Marta Zalacain; Sebastian J Schober; Andrej Lissat; William R English; Nicola Baldini; Dominique Heymann
Journal:  EMBO Mol Med       Date:  2020-10-13       Impact factor: 12.137

8.  Pyridazinone Derivatives Limit Osteosarcoma-Cells Growth In Vitro and In Vivo.

Authors:  Aurélie Moniot; Julien Braux; Camille Bour; Christine Guillaume; Fabien Lamret; Ingrid Allart-Simon; Sandra Audonnet; Sarah Renault; Francoise Rédini; Marie Laronze-Cochard; Janos Sapi; Sophie C Gangloff; Stéphane Gérard; Frédéric Velard
Journal:  Cancers (Basel)       Date:  2021-11-28       Impact factor: 6.639

9.  A targeted combinatorial therapy for Ewing's sarcoma.

Authors:  Fahad Y Sabei; Olena Taratula; Hassan A Albarqi; Adel M Al-Fatease; Abraham S Moses; Ananiya A Demessie; Youngrong Park; Walter K Vogel; Ellie Esfandiari Nazzaro; Monika A Davare; Adam Alani; Mark Leid; Oleh Taratula
Journal:  Nanomedicine       Date:  2021-07-23       Impact factor: 6.096

10.  Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice.

Authors:  Maria Eugenia Marques da Costa; Estelle Daudigeos-Dubus; Anne Gomez-Brouchet; Olivia Bawa; Valerie Rouffiac; Massimo Serra; Katia Scotlandi; Conceição Santos; Birgit Geoerger; Nathalie Gaspar
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.